Jason W Wagner

US Patent:

20090221555, Sep 3, 2009

Filed:

Oct 23, 2007

Appl. No.:

12/162851

Inventors:

Gulzar Ahmed - Voorhees NJ, US
Adolph Bohnstedt - Burlington NJ, US
Henry Joseph Breslin - Lansdale PA, US
Jason Burke - Charlottesville VA, US
Matthew A. Curry - Coatesville PA, US
James L. Diebold - Norristown PA, US
Bruce Dorsey - Ambler PA, US
Benjamin J. Dugan - Glen Mills PA, US
Daming Feng - East Windsor NJ, US
Diane E. Gingrich - Downingtown PA, US
Tao Guo - Dayton NJ, US
Keith S. Learn - Perkiomenville PA, US
Joseph G. Lisko - Glenmoore PA, US
Eugen Mesaros - Philadelphia PA, US
Karen Milkiewicz - Exton PA, US
Gregory R. Ott - Media PA, US
Jonathan Parrish - New York NY, US
Jay P. Theroff - West Chester PA, US
Tho V. Thieu - Ambler PA, US
Rabindranath Tripathy - Churchville PA, US
Theodore L. Underiner - Malvern PA, US
Jason C. Wagner - Coatesville PA, US
Linda Weinberg - Villanova PA, US
Gregory J. Wells - West Chester PA, US
Ming You - Plainsboro NJ, US
Craig A. Zificsak - Downingtown PA, US

Assignee:

Cephalon, Inc. - Frazer PA
Pharmacopeia Drug Discovery, Inc. - Cranbury NJ

International Classification:

A61K 31/55
C07D 239/02
A61K 31/505
C07D 403/00
C07D 413/14
A61K 31/5377
C07D 413/00
C07D 403/14

US Classification:

51421706, 544323, 514275, 540601, 5142355, 544122

Abstract:

The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R, R, R, R, R, A, A, A, A, and A, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.